Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-708-3p APAF1 0.14 0.89698 -0.17 0.88665 mirMAP -0.11 0.0011 NA
2 hsa-miR-324-5p ATM -0.5 0.53742 0.19 0.86463 miRanda -0.12 0.00155 NA
3 hsa-miR-455-5p ATM -0.14 0.86574 0.19 0.86463 miRanda -0.12 0.00128 NA
4 hsa-miR-590-5p ATM -0.55 0.47274 0.19 0.86463 mirMAP -0.1 0.00142 NA
5 hsa-miR-30a-5p CASP3 0.22 0.93395 -0.16 0.90316 miRNATAP -0.2 6.0E-5 NA
6 hsa-miR-143-3p CASP8 0.37 0.92734 -0.27 0.82859 MirTarget -0.11 0.00055 NA
7 hsa-miR-133b CCNB1 0.39 0.56076 -0.28 0.85013 miRanda -0.13 0 NA
8 hsa-miR-139-5p CCNB1 -0.08 0.92869 -0.28 0.85013 miRanda -0.18 0.00084 NA
9 hsa-let-7c-5p CCNB2 -0.06 0.9749 -0.2 0.87078 miRNAWalker2 validate -0.19 0 NA
10 hsa-miR-23b-3p CCNB2 -0.11 0.96135 -0.2 0.87078 miRNAWalker2 validate -0.33 0.00011 NA
11 hsa-miR-16-5p CCND1 0.01 0.99448 -0.25 0.89067 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.13 0.00823 23991964; 22922827; 18483394 At the molecular level our results further revealed that cyclin D1 expression was negatively regulated by miR-16;CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR;Truncation in CCND1 mRNA alters miR 16 1 regulation in mantle cell lymphoma; Furthermore we demonstrated that this truncation alters miR-16-1 binding sites and through the use of reporter constructs we were able to show that miR-16-1 regulates CCND1 mRNA expression; This study introduces the role of miR-16-1 in the regulation of CCND1 in MCL
12 hsa-miR-195-5p CCND1 0.34 0.74962 -0.25 0.89067 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.14 0.00272 21350001; 26631043; 25823925 Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein p = 0.013 p = 0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma
13 hsa-miR-29c-3p CCND1 0.16 0.94272 -0.25 0.89067 mirMAP -0.14 0.00181 NA
14 hsa-miR-125b-5p CCNE1 0.04 0.98059 -0.28 0.73651 miRNAWalker2 validate -0.15 0.00074 NA
15 hsa-miR-195-5p CCNE1 0.34 0.74962 -0.28 0.73651 miRNAWalker2 validate; MirTarget; miRNATAP -0.18 0.00302 24402230 Furthermore through qPCR and western blot assays we showed that overexpression of miR-195-5p reduced CCNE1 mRNA and protein levels respectively
16 hsa-miR-26a-5p CCNE2 0.01 0.99772 -0.15 0.8473 miRNAWalker2 validate; miRTarBase; miRNATAP -0.36 0.00084 24116110; 21901171 The loss of miR 26a mediated post transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival; The in vitro and in vivo assays showed that overexpression of miR-26a resulted in cell cycle arrest inhibited cell proliferation and decreased tumor growth which was associated with cyclin E2 downregulation;We also show that enforced expression of miR-26a in AML cells is able to inhibit cell cycle progression by downregulating cyclin E2 expression
17 hsa-miR-30a-5p CCNE2 0.22 0.93395 -0.15 0.8473 miRNATAP -0.44 0 NA
18 hsa-miR-34a-5p CCNE2 -0.5 0.74203 -0.15 0.8473 miRNAWalker2 validate; miRTarBase; miRNATAP -0.22 0.00018 NA
19 hsa-miR-34c-5p CCNE2 -0.02 0.95279 -0.15 0.8473 miRNAWalker2 validate; miRTarBase; PITA; miRanda; miRNATAP -0.28 0 NA
20 hsa-let-7c-5p CCNG1 -0.06 0.9749 -0.02 0.9911 miRNAWalker2 validate -0.11 0.00149 NA
21 hsa-let-7e-5p CCNG1 0.21 0.92234 -0.02 0.9911 miRNAWalker2 validate -0.23 0.00082 NA
22 hsa-miR-100-5p CCNG1 0.02 0.99282 -0.02 0.9911 miRNAWalker2 validate -0.12 0.00075 NA
23 hsa-miR-23b-3p CCNG1 -0.11 0.96135 -0.02 0.9911 MirTarget; miRNATAP -0.22 0.0086 26872615 MiR 23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression; Dual-luciferase reporter assay and a xenograft mouse model were used to examine the expression of miR-23b and its target gene CCNG1; Dual-luciferase reporter assay showed that miR-23b bound with the 3' untranslated region of CCNG1; Furthermore miR-23b inhibited tumor growth and suppressed CCNG1 expression in vitro; Our findings show that miR-23b may inhibit ovarian cancer tumorigenesis and progression by downregulating CCNG1 and the expression of the relevant genes
24 hsa-miR-106a-5p CCNG2 -0.2 0.80221 -0.11 0.92934 MirTarget; miRNATAP -0.13 0.00134 NA
25 hsa-miR-106b-5p CCNG2 -0.3 0.86929 -0.11 0.92934 MirTarget; miRNATAP -0.12 0.00599 NA
26 hsa-miR-17-5p CCNG2 -0.18 0.93454 -0.11 0.92934 MirTarget; TargetScan; miRNATAP -0.15 2.0E-5 NA
27 hsa-miR-20a-5p CCNG2 -0.18 0.92812 -0.11 0.92934 MirTarget; miRNATAP -0.12 0.00028 NA
28 hsa-miR-224-5p CCNG2 -0.24 0.85735 -0.11 0.92934 mirMAP -0.13 0 NA
29 hsa-miR-29a-5p CCNG2 -0.32 0.60044 -0.11 0.92934 mirMAP -0.11 0.00322 NA
30 hsa-miR-331-5p CCNG2 -0.45 0.25036 -0.11 0.92934 miRNATAP -0.12 0.00824 NA
31 hsa-miR-335-3p CCNG2 -0.24 0.8845 -0.11 0.92934 MirTarget; mirMAP -0.16 1.0E-5 NA
32 hsa-miR-503-5p CCNG2 0.18 0.7664 -0.11 0.92934 miRNAWalker2 validate -0.1 0.00027 NA
33 hsa-miR-93-5p CCNG2 -0.61 0.8253 -0.11 0.92934 miRNAWalker2 validate; MirTarget; miRNATAP -0.14 0.00129 NA
34 hsa-miR-23b-3p CDK2 -0.11 0.96135 -0.01 0.99411 miRNAWalker2 validate -0.17 0.00275 NA
35 hsa-miR-195-5p CDK4 0.34 0.74962 -0.06 0.97429 miRNAWalker2 validate; miRTarBase -0.18 0 NA
36 hsa-miR-34c-5p CDK4 -0.02 0.95279 -0.06 0.97429 miRNAWalker2 validate; miRTarBase -0.11 0.00308 NA
37 hsa-miR-21-5p CDK6 -0.15 0.97024 0.26 0.8515 miRNAWalker2 validate; mirMAP -0.32 5.0E-5 NA
38 hsa-miR-22-3p CDK6 0.06 0.98656 0.26 0.8515 miRNAWalker2 validate -0.27 0.00121 NA
39 hsa-let-7c-5p CDKN1A -0.06 0.9749 0.1 0.95314 MirTarget -0.15 0.0033 NA
40 hsa-miR-101-3p CDKN1A 0.01 0.99704 0.1 0.95314 MirTarget -0.4 4.0E-5 NA
41 hsa-miR-708-5p CDKN1A -0.03 0.97493 0.1 0.95314 MirTarget -0.14 0.00964 NA
42 hsa-let-7g-5p CDKN2A -0.2 0.92299 1.38 0.01803 miRNAWalker2 validate; miRTarBase -0.54 0.00297 NA
43 hsa-miR-139-5p CHEK1 -0.08 0.92869 -0.28 0.78554 miRanda -0.13 0.00213 NA
44 hsa-miR-195-5p CHEK1 0.34 0.74962 -0.28 0.78554 MirTarget; miRNATAP -0.16 0.00025 25840419 MiR 195 suppresses non small cell lung cancer by targeting CHEK1; We discovered that CHEK1 was a direct target of miR-195 which decreased CHEK1 expression in lung cancer cells
45 hsa-miR-497-5p CHEK1 -0.01 0.98915 -0.28 0.78554 MirTarget; miRNATAP -0.21 5.0E-5 24464213 Checkpoint kinase 1 is negatively regulated by miR 497 in hepatocellular carcinoma; In silico analysis showed that CHEK1 was a candidate target of miR-497 which was previously found to be downregulated in HCC by us; To test whether miR-497 could bind to 3'untranslated region 3'UTR of CHEK1 luciferase reporter assay was conducted; The result revealed that miR-497 could bind to the 3'untranslated region 3'UTR of CHEK1 mRNA; Western blot showed that ectopic expression of miR-497 suppressed the CHEK1 expression and inhibition of miR-497 led to significant upregulation of CHEK1; Finally miR-497 expression was measured in the same 30 HCC samples and the correlation between miR-497 and CHEK1 was analyzed; The results indicated that miR-497 was downregulated in HCC and had a significant negative correlation with CHEK1; Taken together these results demonstrated that CHEK1 was negatively regulated by miR-497 and the overexpressed CHEK1 was resulted from the downregulated miR-497 in HCC which provided a potential molecular target for HCC therapy
46 hsa-miR-139-5p CYCS -0.08 0.92869 -0.08 0.96574 miRanda -0.18 7.0E-5 NA
47 hsa-miR-34c-3p CYCS -0.07 0.82545 -0.08 0.96574 mirMAP -0.1 0.008 NA
48 hsa-miR-34c-5p CYCS -0.02 0.95279 -0.08 0.96574 miRanda -0.16 0.00033 NA
49 hsa-miR-106a-5p FAS -0.2 0.80221 -0.35 0.70281 miRNAWalker2 validate; miRTarBase -0.31 0 22431000; 27142596 miR 106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS; Bioinformatic analysis combining with validation experiments identified FAS as a direct target of miR-106a; Moreover a significant inverse correlation was found between miR-106a and FAS expression not only in gastric cancer cell lines but also in gastric cancer specimens; Taken together these findings suggest that ectopicly overexpressed miR-106a may play an oncogenic role in gastric carcinogenesis and impair extrinsic apoptotic pathway through targeting FAS;Functional experiment ascertained that miR-106a interacted with FAS and mediated caspase3 pathway
50 hsa-miR-361-5p FAS -0.14 0.9415 -0.35 0.70281 miRanda -0.42 0.00016 NA
51 hsa-miR-590-5p FAS -0.55 0.47274 -0.35 0.70281 miRanda -0.17 0.00403 NA
52 hsa-miR-98-5p FAS -0.17 0.8988 -0.35 0.70281 miRNAWalker2 validate -0.38 2.0E-5 NA
53 hsa-miR-324-3p GADD45B -0.42 0.66153 0.52 0.61353 MirTarget; miRNATAP -0.22 0.00285 NA
54 hsa-miR-590-3p GADD45B -0.28 0.59127 0.52 0.61353 miRanda -0.23 0 NA
55 hsa-miR-181c-5p GTSE1 0.04 0.96916 -0.25 0.80831 MirTarget -0.2 4.0E-5 NA
56 hsa-let-7a-3p IGF1 -0.22 0.85543 0.01 0.98747 mirMAP -1.08 0 NA
57 hsa-let-7f-1-3p IGF1 -0.31 0.69341 0.01 0.98747 mirMAP -1.34 0 NA
58 hsa-miR-1275 IGF1 -0.83 0.08038 0.01 0.98747 MirTarget; PITA -0.38 5.0E-5 NA
59 hsa-miR-130b-3p IGF1 -0.22 0.82466 0.01 0.98747 MirTarget -1.33 0 NA
60 hsa-miR-148a-5p IGF1 -0.45 0.74842 0.01 0.98747 mirMAP -0.73 0 NA
61 hsa-miR-15b-3p IGF1 -0.56 0.60918 0.01 0.98747 mirMAP -1.37 0 NA
62 hsa-miR-16-1-3p IGF1 0.15 0.73374 0.01 0.98747 mirMAP -0.87 0 NA
63 hsa-miR-186-5p IGF1 -0.32 0.85413 0.01 0.98747 mirMAP -1.35 0 NA
64 hsa-miR-19a-3p IGF1 -0.21 0.84464 0.01 0.98747 MirTarget -0.99 0 NA
65 hsa-miR-19b-1-5p IGF1 -0.01 0.98851 0.01 0.98747 mirMAP -0.96 0 NA
66 hsa-miR-19b-3p IGF1 -0.03 0.98666 0.01 0.98747 MirTarget -1.19 0 NA
67 hsa-miR-20a-3p IGF1 0.46 0.57674 0.01 0.98747 mirMAP -0.83 0 NA
68 hsa-miR-224-3p IGF1 0.11 0.74909 0.01 0.98747 mirMAP -0.32 0.00753 NA
69 hsa-miR-26b-5p IGF1 -0.02 0.99038 0.01 0.98747 mirMAP -1.33 0 NA
70 hsa-miR-27a-3p IGF1 -0.12 0.9588 0.01 0.98747 miRNAWalker2 validate; miRTarBase -1.33 0 NA
71 hsa-miR-29a-3p IGF1 0.01 0.99698 0.01 0.98747 MirTarget -1.22 0 NA
72 hsa-miR-29b-3p IGF1 -0.1 0.95899 0.01 0.98747 MirTarget -1.13 0 25592039 Luciferase reporter assays were conducted to determine the association between miR-29b and the insulin-like growth factor 1 IGF1 3' untranslated region 3'UTR; IGF1 an activator of PI3K/Akt signaling was confirmed as a novel target of miR-29b
73 hsa-miR-301a-3p IGF1 -0.11 0.83169 0.01 0.98747 MirTarget -0.72 0 NA
74 hsa-miR-32-3p IGF1 -0.57 0.13133 0.01 0.98747 mirMAP -0.85 0 NA
75 hsa-miR-320a IGF1 -0.42 0.8402 0.01 0.98747 miRNATAP -0.53 0.00309 NA
76 hsa-miR-33a-3p IGF1 -0.79 0.01052 0.01 0.98747 MirTarget -0.71 0 NA
77 hsa-miR-361-5p IGF1 -0.14 0.9415 0.01 0.98747 PITA; mirMAP -0.76 0.00313 NA
78 hsa-miR-362-5p IGF1 -0.27 0.75202 0.01 0.98747 mirMAP -0.69 0 NA
79 hsa-miR-369-3p IGF1 0.12 0.8323 0.01 0.98747 mirMAP -0.42 0.00732 NA
80 hsa-miR-374b-3p IGF1 -0.05 0.86075 0.01 0.98747 mirMAP -0.9 0 NA
81 hsa-miR-376b-3p IGF1 -0.01 0.98243 0.01 0.98747 mirMAP -0.4 0.00219 NA
82 hsa-miR-377-3p IGF1 -0.04 0.89351 0.01 0.98747 mirMAP -0.35 0.00945 NA
83 hsa-miR-421 IGF1 -0.18 0.7347 0.01 0.98747 PITA -0.68 0 NA
84 hsa-miR-450b-5p IGF1 -0.01 0.98315 0.01 0.98747 MirTarget; PITA; mirMAP; miRNATAP -0.44 0.00527 NA
85 hsa-miR-452-5p IGF1 -0.05 0.97387 0.01 0.98747 MirTarget; mirMAP -0.39 0.00722 NA
86 hsa-miR-454-3p IGF1 -0.1 0.84355 0.01 0.98747 MirTarget -1.21 0 NA
87 hsa-miR-486-5p IGF1 -0.55 0.6964 0.01 0.98747 PITA; miRNATAP -0.28 0.00602 NA
88 hsa-miR-576-5p IGF1 -0.51 0.41719 0.01 0.98747 PITA; mirMAP; miRNATAP -1.08 0 NA
89 hsa-miR-577 IGF1 -1.06 0.32606 0.01 0.98747 PITA -0.61 0 NA
90 hsa-miR-590-3p IGF1 -0.28 0.59127 0.01 0.98747 MirTarget; miRanda; mirMAP; miRNATAP -0.9 0 NA
91 hsa-miR-592 IGF1 -0.18 0.85623 0.01 0.98747 mirMAP -0.18 0.00559 NA
92 hsa-miR-629-5p IGF1 -0.39 0.79854 0.01 0.98747 mirMAP -0.58 3.0E-5 NA
93 hsa-miR-940 IGF1 -0.23 0.68006 0.01 0.98747 MirTarget; PITA; miRNATAP -0.57 0 NA
94 hsa-let-7a-3p IGFBP3 -0.22 0.85543 0.57 0.72672 miRNATAP -0.43 0 NA
95 hsa-miR-197-3p IGFBP3 -0.46 0.79492 0.57 0.72672 MirTarget; miRNATAP -0.35 2.0E-5 NA
96 hsa-miR-19a-3p IGFBP3 -0.21 0.84464 0.57 0.72672 MirTarget; miRNATAP -0.41 0 NA
97 hsa-miR-19b-3p IGFBP3 -0.03 0.98666 0.57 0.72672 MirTarget; miRNATAP -0.48 0 NA
98 hsa-miR-224-5p IGFBP3 -0.24 0.85735 0.57 0.72672 MirTarget -0.3 0 NA
99 hsa-miR-339-5p IGFBP3 -0.3 0.71291 0.57 0.72672 miRanda -0.32 0 NA
100 hsa-miR-374a-5p IGFBP3 -0.34 0.76692 0.57 0.72672 MirTarget; mirMAP -0.5 0 NA
101 hsa-miR-374b-5p IGFBP3 -0.29 0.8357 0.57 0.72672 MirTarget -0.54 0 NA
102 hsa-miR-375 IGFBP3 -0.69 0.83172 0.57 0.72672 miRNAWalker2 validate -0.17 0.00046 NA
103 hsa-miR-590-3p IGFBP3 -0.28 0.59127 0.57 0.72672 miRanda -0.33 0 NA
104 hsa-miR-590-5p IGFBP3 -0.55 0.47274 0.57 0.72672 miRanda -0.42 0 NA
105 hsa-miR-143-3p MDM2 0.37 0.92734 -0.49 0.72349 miRNAWalker2 validate -0.16 0.00124 NA
106 hsa-let-7b-5p MDM4 -0.23 0.93895 0.25 0.82318 miRNAWalker2 validate; MirTarget -0.14 0.00444 NA
107 hsa-miR-150-5p PERP -0.38 0.83879 0.23 0.91127 MirTarget -0.17 0 NA
108 hsa-miR-629-3p PERP -0.5 0.33397 0.23 0.91127 MirTarget -0.12 0.00543 NA
109 hsa-miR-200b-3p PMAIP1 -0.43 0.86396 0.02 0.98032 MirTarget; TargetScan -0.15 0.00941 NA
110 hsa-miR-195-5p PPM1D 0.34 0.74962 -0.19 0.83465 MirTarget; miRNATAP -0.1 0.00097 NA
111 hsa-miR-26b-5p PPM1D -0.02 0.99038 -0.19 0.83465 miRNAWalker2 validate -0.12 0.00263 NA
112 hsa-miR-29a-3p PPM1D 0.01 0.99698 -0.19 0.83465 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.16 5.0E-5 NA
113 hsa-miR-29b-3p PPM1D -0.1 0.95899 -0.19 0.83465 MirTarget; miRNATAP -0.11 0.00016 NA
114 hsa-miR-106a-5p PTEN -0.2 0.80221 -0.27 0.8446 miRNATAP -0.14 0.00145 26097565; 26318586 miR 106a promotes growth and metastasis of non small cell lung cancer by targeting PTEN; Furthermore the presence of miR-106a was inversely correlated with PTEN in NSCLC tissues; Overall this study suggested that miR-106a inhibited the growth and metastasis of NSCLC cells by decreasing PTEN expression;Further pterostilbene through downregulation of miR-17-5p and miR-106a-5p expression both in tumors and systemic circulation rescued PTEN mRNA and protein levels leading to reduced tumor growth in vivo
115 hsa-miR-188-5p PTEN -0.57 0.32482 -0.27 0.8446 MirTarget; PITA; miRNATAP -0.1 0.00127 NA
116 hsa-miR-29b-3p PTEN -0.1 0.95899 -0.27 0.8446 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.12 0.0055 26471361; 23179556; 26063204; 21359530 Mechanistically ATDC exerted its oncogenic effects by suppressing miR-29 and subsequent upregulation of DNMT3A leading to DNA methylation and silencing of the tumor suppressor PTEN;Anticancer role of MUC1 aptamer miR 29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation; Our study indicated that Chi-29b chimera can effectively exert antitumor effect through specific delivery of miR-29b into OVCAR-3 tumor cells subsequently reexpressing PTEN gene and inducing cell apoptosis;Furthermore the dual-luciferase reporter assay demonstrated that miR-29b inhibited the expression of the luciferase gene containing the 3'-UTRs of MMP2 and PTEN mRNA;In contrast enhanced miR-29b expression by transfection with pre-miR-29b decreased the expression of PTEN and impaired apoptosis increasing tumor cell migration and invasion; Moreover PTEN was shown to be a direct target of miR-29b and was also shown to contribute to the miR-29b-mediated effects on cell invasion; Modulation of miR-29b altered the role of PTEN involved in cell migration and invasion; Aberrant expression of miR-29b which modulates PTEN expression can contribute to migration invasion and anti-apoptosis
117 hsa-miR-146b-5p RFWD2 -0.4 0.83751 0.13 0.92354 miRNATAP -0.12 4.0E-5 NA
118 hsa-miR-338-3p RPRM 0.49 0.78848 0.53 0.54344 miRanda -0.36 0.00289 NA
119 hsa-miR-375 RPRM -0.69 0.83172 0.53 0.54344 miRanda -0.5 0 NA
120 hsa-miR-501-3p RPRM -0.75 0.55276 0.53 0.54344 miRNATAP -0.62 4.0E-5 NA
121 hsa-miR-100-5p RRM2 0.02 0.99282 -0.25 0.87456 miRNAWalker2 validate -0.25 0 NA
122 hsa-miR-125a-5p RRM2 -0 0.99916 -0.25 0.87456 miRanda -0.27 9.0E-5 NA
123 hsa-miR-199a-5p RRM2 0.16 0.9358 -0.25 0.87456 miRanda -0.24 4.0E-5 NA
124 hsa-miR-199b-5p RRM2 -0.04 0.97717 -0.25 0.87456 miRanda -0.15 0.00321 NA
125 hsa-miR-217 RRM2 0.34 0.761 -0.25 0.87456 miRanda -0.2 0 NA
126 hsa-miR-26a-5p RRM2 0.01 0.99772 -0.25 0.87456 miRNAWalker2 validate -0.42 3.0E-5 NA
127 hsa-miR-30a-5p RRM2 0.22 0.93395 -0.25 0.87456 miRNAWalker2 validate -0.5 0 NA
128 hsa-miR-140-5p RRM2B -0.23 0.84733 -0.42 0.72245 miRanda -0.18 0.00211 NA
129 hsa-miR-142-3p RRM2B -0.15 0.9461 -0.42 0.72245 miRNAWalker2 validate; miRanda -0.15 0 NA
130 hsa-miR-30e-5p RRM2B -0.07 0.97968 -0.42 0.72245 mirMAP -0.19 0.00223 NA
131 hsa-miR-369-3p RRM2B 0.12 0.8323 -0.42 0.72245 mirMAP -0.11 0.00769 NA
132 hsa-miR-495-3p RRM2B 0 0.99753 -0.42 0.72245 mirMAP -0.17 0.0005 NA
133 hsa-miR-7-1-3p RRM2B -0.46 0.6659 -0.42 0.72245 mirMAP -0.16 1.0E-5 NA
134 hsa-miR-335-5p SERPINB5 -0.03 0.97338 1 0.44591 miRNAWalker2 validate -0.58 0.00012 NA
135 hsa-miR-148a-3p SERPINE1 -0.1 0.97698 0.97 0.43183 miRNATAP -0.63 0 NA
136 hsa-miR-148a-5p SERPINE1 -0.45 0.74842 0.97 0.43183 miRNATAP -0.49 0 NA
137 hsa-miR-2110 SERPINE1 -0.32 0.25098 0.97 0.43183 miRNATAP -0.26 0.00814 NA
138 hsa-miR-301a-3p SERPINE1 -0.11 0.83169 0.97 0.43183 miRNAWalker2 validate; miRTarBase -0.4 1.0E-5 NA
139 hsa-miR-30b-5p SERPINE1 -0.01 0.99462 0.97 0.43183 MirTarget -0.51 0 25170877 miR-30b may function as a novel tumor suppressor gene in gastric cancer by targeting PAI-1 and regulating the apoptosis of cancer cells
140 hsa-miR-30c-5p SERPINE1 -0.3 0.86581 0.97 0.43183 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.66 0 NA
141 hsa-miR-30d-5p SERPINE1 -0.17 0.95173 0.97 0.43183 miRNATAP -0.62 0 NA
142 hsa-miR-378a-5p SERPINE1 -0.56 0.72488 0.97 0.43183 MirTarget -0.55 0 NA
143 hsa-miR-421 SERPINE1 -0.18 0.7347 0.97 0.43183 miRanda -0.42 2.0E-5 NA
144 hsa-miR-425-5p SERPINE1 -0.35 0.84598 0.97 0.43183 MirTarget; miRNATAP -0.54 0 NA
145 hsa-miR-452-3p SERPINE1 -0.17 0.79901 0.97 0.43183 mirMAP -0.39 0 NA
146 hsa-miR-514a-3p SERPINE1 0.23 0.69823 0.97 0.43183 MirTarget -0.14 0.00373 NA
147 hsa-miR-590-3p SERPINE1 -0.28 0.59127 0.97 0.43183 miRanda -0.43 0 NA
148 hsa-miR-629-3p SERPINE1 -0.5 0.33397 0.97 0.43183 MirTarget -0.28 0.00066 NA
149 hsa-miR-769-5p SERPINE1 -0.31 0.7357 0.97 0.43183 MirTarget; miRNATAP -0.6 1.0E-5 NA
150 hsa-miR-942-5p SERPINE1 -0.51 0.50778 0.97 0.43183 MirTarget -0.45 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 REGULATION OF CELL CYCLE 25 949 6.983e-23 3.249e-19
2 CELL CYCLE PROCESS 24 1081 4.194e-20 9.757e-17
3 CELL CYCLE 25 1316 1.973e-19 2.295e-16
4 NEGATIVE REGULATION OF CELL CYCLE 18 433 1.689e-19 2.295e-16
5 MITOTIC CELL CYCLE 21 766 3.405e-19 3.169e-16
6 REGULATION OF CELL DEATH 24 1472 5.18e-17 4.017e-14
7 POSITIVE REGULATION OF CELL DEATH 18 605 6.31e-17 4.194e-14
8 RESPONSE TO ABIOTIC STIMULUS 21 1024 1.239e-16 7.205e-14
9 REGULATION OF CELL CYCLE ARREST 11 108 2.514e-16 1.3e-13
10 REGULATION OF CELL PROLIFERATION 23 1496 1.195e-15 5.559e-13
11 SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 11 127 1.577e-15 6.672e-13
12 POSITIVE REGULATION OF CELL CYCLE PROCESS 13 247 2.104e-15 8.158e-13
13 CELL CYCLE PHASE TRANSITION 13 255 3.182e-15 1.139e-12
14 CELL CYCLE CHECKPOINT 12 194 4.223e-15 1.404e-12
15 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 10 98 6.438e-15 1.997e-12
16 NEGATIVE REGULATION OF CELL CYCLE PROCESS 12 214 1.378e-14 4.007e-12
17 REGULATION OF MITOTIC CELL CYCLE 15 468 1.529e-14 4.186e-12
18 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 22 1492 1.641e-14 4.243e-12
19 REGULATION OF PROTEOLYSIS 17 711 2.126e-14 5.207e-12
20 CELL DEATH 19 1001 2.458e-14 5.719e-12
21 G1 DNA DAMAGE CHECKPOINT 9 73 2.794e-14 6.191e-12
22 RESPONSE TO OXYGEN LEVELS 13 311 4.122e-14 8.718e-12
23 CELLULAR RESPONSE TO STRESS 22 1565 4.387e-14 8.875e-12
24 POSITIVE REGULATION OF CELL CYCLE 13 332 9.52e-14 1.846e-11
25 POSITIVE REGULATION OF CELL CYCLE ARREST 9 85 1.164e-13 2.167e-11
26 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 11 199 2.344e-13 4.195e-11
27 POSITIVE REGULATION OF PROTEOLYSIS 13 363 2.973e-13 5.123e-11
28 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 9 95 3.273e-13 5.439e-11
29 NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION 10 146 3.792e-13 5.882e-11
30 DNA INTEGRITY CHECKPOINT 10 146 3.792e-13 5.882e-11
31 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 10 147 4.063e-13 6.098e-11
32 APOPTOTIC SIGNALING PATHWAY 12 289 4.958e-13 6.991e-11
33 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 11 213 4.946e-13 6.991e-11
34 MITOTIC DNA INTEGRITY CHECKPOINT 9 100 5.259e-13 7.198e-11
35 REGULATION OF PEPTIDASE ACTIVITY 13 392 7.888e-13 1.049e-10
36 CELL CYCLE G1 S PHASE TRANSITION 9 111 1.374e-12 1.728e-10
37 G1 S TRANSITION OF MITOTIC CELL CYCLE 9 111 1.374e-12 1.728e-10
38 ZYMOGEN ACTIVATION 9 112 1.492e-12 1.827e-10
39 REGULATION OF CELL CYCLE PHASE TRANSITION 12 321 1.711e-12 2.042e-10
40 REGULATION OF CELL CYCLE PROCESS 14 558 3.798e-12 4.418e-10
41 REGULATION OF APOPTOTIC SIGNALING PATHWAY 12 363 7.229e-12 8.204e-10
42 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 15 720 7.645e-12 8.469e-10
43 MITOTIC CELL CYCLE CHECKPOINT 9 139 1.069e-11 1.157e-09
44 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 7 55 2.005e-11 2.12e-09
45 SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE 8 96 2.16e-11 2.234e-09
46 INTRINSIC APOPTOTIC SIGNALING PATHWAY 9 152 2.399e-11 2.426e-09
47 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 9 154 2.699e-11 2.672e-09
48 REGULATION OF TRANSFERASE ACTIVITY 16 946 2.894e-11 2.805e-09
49 REGULATION OF PROTEIN MODIFICATION PROCESS 20 1710 3.197e-11 3.036e-09
50 REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 9 162 4.257e-11 3.962e-09
51 RESPONSE TO DRUG 12 431 5.31e-11 4.844e-09
52 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 9 171 6.916e-11 6.189e-09
53 INTRACELLULAR SIGNAL TRANSDUCTION 19 1572 7.155e-11 6.282e-09
54 RESPONSE TO LIPID 15 888 1.466e-10 1.263e-08
55 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 16 1087 2.268e-10 1.919e-08
56 RESPONSE TO STEROID HORMONE 12 497 2.73e-10 2.268e-08
57 NEGATIVE REGULATION OF CELL PROLIFERATION 13 643 3.761e-10 3.07e-08
58 RESPONSE TO ESTROGEN 9 218 6.009e-10 4.821e-08
59 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 8 153 9.239e-10 7.286e-08
60 CELL CYCLE ARREST 8 154 9.731e-10 7.546e-08
61 REGULATION OF PHOSPHORUS METABOLIC PROCESS 18 1618 1.08e-09 8.239e-08
62 REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 7 97 1.19e-09 8.93e-08
63 RESPONSE TO METAL ION 10 333 1.313e-09 9.696e-08
64 REGENERATION 8 161 1.385e-09 1.007e-07
65 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 18 1656 1.569e-09 1.123e-07
66 CELL DIVISION 11 460 1.904e-09 1.342e-07
67 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 11 470 2.384e-09 1.656e-07
68 RESPONSE TO ORGANIC CYCLIC COMPOUND 14 917 2.617e-09 1.791e-07
69 RESPONSE TO ALCOHOL 10 362 2.932e-09 1.977e-07
70 CELLULAR RESPONSE TO ABIOTIC STIMULUS 9 263 3.13e-09 2.081e-07
71 CELLULAR RESPONSE TO EXTERNAL STIMULUS 9 264 3.236e-09 2.091e-07
72 AGING 9 264 3.236e-09 2.091e-07
73 PROTEIN MATURATION 9 265 3.345e-09 2.132e-07
74 POSITIVE REGULATION OF CATALYTIC ACTIVITY 17 1518 3.444e-09 2.166e-07
75 REGULATION OF KINASE ACTIVITY 13 776 3.68e-09 2.283e-07
76 RESPONSE TO X RAY 5 30 4.376e-09 2.679e-07
77 POSITIVE REGULATION OF MOLECULAR FUNCTION 18 1791 5.485e-09 3.315e-07
78 RESPONSE TO EXTERNAL STIMULUS 18 1821 7.138e-09 4.258e-07
79 RESPONSE TO OXYGEN CONTAINING COMPOUND 16 1381 7.32e-09 4.311e-07
80 RESPONSE TO UV 7 126 7.48e-09 4.35e-07
81 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 13 829 8.123e-09 4.66e-07
82 REPLICATIVE SENESCENCE 4 12 8.213e-09 4.66e-07
83 NEURON APOPTOTIC PROCESS 5 35 9.892e-09 5.546e-07
84 RESPONSE TO RADIATION 10 413 1.032e-08 5.705e-07
85 DNA REPLICATION 8 208 1.042e-08 5.705e-07
86 NEGATIVE REGULATION OF CELL DEATH 13 872 1.483e-08 8.025e-07
87 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 13 876 1.566e-08 8.376e-07
88 REGULATION OF PROTEIN STABILITY 8 221 1.673e-08 8.846e-07
89 REGULATION OF FIBROBLAST PROLIFERATION 6 81 1.707e-08 8.924e-07
90 RESPONSE TO IONIZING RADIATION 7 145 1.986e-08 1.015e-06
91 ORGAN REGENERATION 6 83 1.979e-08 1.015e-06
92 RESPONSE TO ESTRADIOL 7 146 2.083e-08 1.042e-06
93 NEGATIVE REGULATION OF MOLECULAR FUNCTION 14 1079 2.078e-08 1.042e-06
94 RESPONSE TO TOXIC SUBSTANCE 8 241 3.281e-08 1.624e-06
95 RESPONSE TO INORGANIC SUBSTANCE 10 479 4.185e-08 2.05e-06
96 NEURON DEATH 5 47 4.588e-08 2.224e-06
97 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 6 98 5.393e-08 2.587e-06
98 NEGATIVE REGULATION OF CELL CYCLE ARREST 4 20 7.941e-08 3.77e-06
99 POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 5 53 8.505e-08 3.957e-06
100 INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 5 53 8.505e-08 3.957e-06
101 RESPONSE TO ENDOGENOUS STIMULUS 15 1450 1.137e-07 5.237e-06
102 RESPONSE TO NITROGEN COMPOUND 12 859 1.227e-07 5.598e-06
103 REGULATION OF RESPONSE TO STRESS 15 1468 1.336e-07 6.036e-06
104 REGULATION OF CELL CYCLE G2 M PHASE TRANSITION 5 59 1.47e-07 6.577e-06
105 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 7 200 1.806e-07 8.002e-06
106 RESPONSE TO HORMONE 12 893 1.868e-07 8.199e-06
107 HISTONE PHOSPHORYLATION 4 25 2.058e-07 8.948e-06
108 POSITIVE REGULATION OF MITOTIC CELL CYCLE 6 123 2.095e-07 9.024e-06
109 RESPONSE TO EXTRACELLULAR STIMULUS 9 441 2.656e-07 1.134e-05
110 CELL AGING 5 67 2.801e-07 1.185e-05
111 PROTEIN STABILIZATION 6 131 3.043e-07 1.275e-05
112 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 13 1135 3.224e-07 1.339e-05
113 REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 4 28 3.315e-07 1.365e-05
114 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 14 1360 3.67e-07 1.498e-05
115 CELL CYCLE G2 M PHASE TRANSITION 6 138 4.138e-07 1.674e-05
116 NEGATIVE REGULATION OF B CELL ACTIVATION 4 30 4.424e-07 1.759e-05
117 NEGATIVE REGULATION OF CELL MATRIX ADHESION 4 30 4.424e-07 1.759e-05
118 CELLULAR RESPONSE TO OXYGEN LEVELS 6 143 5.103e-07 2.012e-05
119 NEGATIVE REGULATION OF CELL COMMUNICATION 13 1192 5.643e-07 2.207e-05
120 NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 32 5.788e-07 2.241e-05
121 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 8 351 5.829e-07 2.241e-05
122 PROTEOLYSIS 13 1208 6.567e-07 2.505e-05
123 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 8 360 7.054e-07 2.669e-05
124 T CELL HOMEOSTASIS 4 34 7.441e-07 2.77e-05
125 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 4 34 7.441e-07 2.77e-05
126 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 12 1036 9.133e-07 3.346e-05
127 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 12 1036 9.133e-07 3.346e-05
128 REGULATION OF CELLULAR RESPONSE TO STRESS 10 691 1.228e-06 4.438e-05
129 REGULATION OF CELL MATRIX ADHESION 5 90 1.23e-06 4.438e-05
130 POSITIVE REGULATION OF CELL COMMUNICATION 14 1532 1.543e-06 5.522e-05
131 RESPONSE TO CORTICOSTEROID 6 176 1.72e-06 6.07e-05
132 REGULATION OF CELLULAR PROTEIN LOCALIZATION 9 552 1.723e-06 6.07e-05
133 RESPONSE TO LIGHT STIMULUS 7 280 1.735e-06 6.07e-05
134 REGULATION OF HYDROLASE ACTIVITY 13 1327 1.893e-06 6.573e-05
135 REGULATION OF CATABOLIC PROCESS 10 731 2.038e-06 7.025e-05
136 RESPONSE TO KETONE 6 182 2.09e-06 7.149e-05
137 NEGATIVE REGULATION OF PHOSPHORYLATION 8 422 2.314e-06 7.861e-05
138 POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 3 13 2.427e-06 8.066e-05
139 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 13 2.427e-06 8.066e-05
140 RESPONSE TO COBALT ION 3 13 2.427e-06 8.066e-05
141 RESPONSE TO NUTRIENT 6 191 2.764e-06 9.12e-05
142 DNA METABOLIC PROCESS 10 758 2.82e-06 9.24e-05
143 LYMPHOCYTE HOMEOSTASIS 4 50 3.606e-06 0.0001173
144 NEGATIVE REGULATION OF B CELL PROLIFERATION 3 15 3.85e-06 0.0001244
145 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 9 616 4.227e-06 0.0001356
146 POSITIVE REGULATION OF RESPONSE TO STIMULUS 15 1929 4.364e-06 0.0001391
147 NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION 4 53 4.565e-06 0.0001435
148 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 4 53 4.565e-06 0.0001435
149 RESPONSE TO MECHANICAL STIMULUS 6 210 4.775e-06 0.0001491
150 NEGATIVE REGULATION OF PROTEOLYSIS 7 329 5.031e-06 0.0001561
151 REGULATION OF B CELL ACTIVATION 5 121 5.305e-06 0.0001624
152 REGULATION OF B CELL PROLIFERATION 4 55 5.3e-06 0.0001624
153 POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 3 17 5.737e-06 0.0001722
154 POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 17 5.737e-06 0.0001722
155 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 3 17 5.737e-06 0.0001722
156 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 15 1977 5.914e-06 0.0001764
157 REGULATION OF DNA METABOLIC PROCESS 7 340 6.24e-06 0.0001849
158 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 5 126 6.467e-06 0.0001905
159 LEUKOCYTE HOMEOSTASIS 4 60 7.521e-06 0.0002201
160 RESPONSE TO ETHANOL 5 136 9.385e-06 0.0002729
161 CELLULAR RESPONSE TO RADIATION 5 137 9.726e-06 0.0002811
162 CELLULAR RESPONSE TO UV 4 66 1.102e-05 0.0003164
163 RESPONSE TO BIOTIC STIMULUS 10 886 1.118e-05 0.0003192
164 POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION 4 68 1.241e-05 0.0003521
165 NEGATIVE REGULATION OF KINASE ACTIVITY 6 250 1.293e-05 0.0003602
166 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 22 1.29e-05 0.0003602
167 REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 5 145 1.281e-05 0.0003602
168 REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 5 148 1.415e-05 0.0003887
169 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 8 541 1.428e-05 0.0003887
170 RESPONSE TO TRANSITION METAL NANOPARTICLE 5 148 1.415e-05 0.0003887
171 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 8 541 1.428e-05 0.0003887
172 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 4 71 1.474e-05 0.0003938
173 RESPONSE TO MAGNESIUM ION 3 23 1.481e-05 0.0003938
174 RESPONSE TO INCREASED OXYGEN LEVELS 3 23 1.481e-05 0.0003938
175 RESPONSE TO HYPEROXIA 3 23 1.481e-05 0.0003938
176 REGULATION OF PROTEIN CATABOLIC PROCESS 7 393 1.599e-05 0.0004226
177 PROTEIN PHOSPHORYLATION 10 944 1.939e-05 0.0005096
178 RESPONSE TO CORTICOSTERONE 3 26 2.165e-05 0.0005641
179 REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 6 274 2.17e-05 0.0005641
180 REGULATION OF NUCLEAR DIVISION 5 163 2.254e-05 0.0005827
181 CELLULAR RESPONSE TO MECHANICAL STIMULUS 4 80 2.366e-05 0.0006083
182 RESPONSE TO CARBOHYDRATE 5 168 2.607e-05 0.0006664
183 REGULATION OF EPITHELIAL CELL PROLIFERATION 6 285 2.708e-05 0.0006885
184 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 29 3.029e-05 0.0007578
185 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 29 3.029e-05 0.0007578
186 REGULATION OF CELL SUBSTRATE ADHESION 5 173 3e-05 0.0007578
187 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 8 602 3.074e-05 0.0007649
188 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 7 437 3.157e-05 0.0007813
189 PHOSPHORYLATION 11 1228 3.271e-05 0.0008053
190 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR 3 30 3.361e-05 0.000823
191 POSITIVE REGULATION OF GENE EXPRESSION 13 1733 3.45e-05 0.0008405
192 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 8 616 3.62e-05 0.0008772
193 REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS 5 181 3.725e-05 0.000898
194 REGULATION OF INTRACELLULAR TRANSPORT 8 621 3.834e-05 0.0009195
195 POSITIVE REGULATION OF CELL PROLIFERATION 9 814 3.901e-05 0.0009307
196 CELLULAR RESPONSE TO LIGHT STIMULUS 4 91 3.933e-05 0.0009336
197 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS 3 32 4.094e-05 0.0009669
198 REGULATION OF GROWTH 8 633 4.39e-05 0.001032
199 CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS 5 188 4.464e-05 0.001041
200 REGULATION OF PROTEIN EXPORT FROM NUCLEUS 3 33 4.497e-05 0.001041
201 REGULATION OF CELL AGING 3 33 4.497e-05 0.001041
202 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 7 465 4.683e-05 0.001079
203 RESPONSE TO REACTIVE OXYGEN SPECIES 5 191 4.813e-05 0.001103
204 PROTEIN DESTABILIZATION 3 34 4.925e-05 0.001123
205 POSITIVE REGULATION OF MAPK CASCADE 7 470 5.01e-05 0.001137
206 RESPONSE TO MOLECULE OF BACTERIAL ORIGIN 6 321 5.26e-05 0.001188
207 NEGATIVE REGULATION OF PROTEIN PROCESSING 3 35 5.378e-05 0.001191
208 RESPONSE TO MINERALOCORTICOID 3 35 5.378e-05 0.001191
209 REPRODUCTION 11 1297 5.399e-05 0.001191
210 NEGATIVE REGULATION OF PROTEIN MATURATION 3 35 5.378e-05 0.001191
211 RESPONSE TO IRON ION 3 35 5.378e-05 0.001191
212 EXTRINSIC APOPTOTIC SIGNALING PATHWAY 4 99 5.472e-05 0.001201
213 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 36 5.859e-05 0.00128
214 REGULATION OF CELL ACTIVATION 7 484 6.029e-05 0.001311
215 REGULATION OF LEUKOCYTE PROLIFERATION 5 206 6.89e-05 0.001491
216 ORGANELLE FISSION 7 496 7.033e-05 0.001515
217 EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 3 39 7.466e-05 0.001601
218 CELLULAR RESPONSE TO ESTROGEN STIMULUS 3 41 8.683e-05 0.001853
219 RESPONSE TO OXIDATIVE STRESS 6 352 8.752e-05 0.00186
220 POSITIVE REGULATION OF HYDROLASE ACTIVITY 9 905 8.853e-05 0.001872
221 REGULATION OF MITOCHONDRION ORGANIZATION 5 218 9.002e-05 0.001895
222 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 5 220 9.397e-05 0.00197
223 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 10 1142 9.741e-05 0.002032
224 MITOTIC NUCLEAR DIVISION 6 361 0.0001005 0.00207
225 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 43 0.0001002 0.00207
226 NEGATIVE REGULATION OF CELL ADHESION 5 223 0.0001002 0.00207
227 RESPONSE TO BACTERIUM 7 528 0.0001039 0.002131
228 REGULATION OF IMMUNE SYSTEM PROCESS 11 1403 0.0001098 0.00224
229 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 6 370 0.000115 0.002338
230 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 6 372 0.0001185 0.002397
231 RESPONSE TO ENDOPLASMIC RETICULUM STRESS 5 233 0.0001231 0.002479
232 REGULATION OF PROTEIN LOCALIZATION 9 950 0.0001282 0.00257
233 RESPONSE TO ANTIBIOTIC 3 47 0.0001309 0.002604
234 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 3 47 0.0001309 0.002604
235 REGULATION OF SMOOTH MUSCLE CELL MIGRATION 3 49 0.0001483 0.002926
236 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 4 128 0.0001484 0.002926
237 NEGATIVE REGULATION OF PEPTIDASE ACTIVITY 5 245 0.0001556 0.003055
238 REGULATION OF LIGASE ACTIVITY 4 130 0.0001575 0.00308
239 GLAND DEVELOPMENT 6 395 0.0001643 0.003198
240 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 7 573 0.0001724 0.003343
241 REGULATION OF NEURON DEATH 5 252 0.0001774 0.003425
242 PROTEIN CATABOLIC PROCESS 7 579 0.0001838 0.003534
243 CIRCADIAN RHYTHM 4 137 0.0001927 0.00369
244 REPRODUCTIVE SYSTEM DEVELOPMENT 6 408 0.0001957 0.003733
245 TISSUE DEVELOPMENT 11 1518 0.0002205 0.004187
246 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 8 801 0.000225 0.004255
247 RAS PROTEIN SIGNAL TRANSDUCTION 4 143 0.0002271 0.004278
248 REGULATION OF CELLULAR LOCALIZATION 10 1277 0.0002438 0.004573
249 REGULATION OF CELL DIVISION 5 272 0.0002528 0.004724
250 REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS 3 59 0.0002579 0.004801
251 RESPONSE TO TEMPERATURE STIMULUS 4 148 0.000259 0.004801
252 DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS 2 12 0.0002804 0.005157
253 POSITIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 2 12 0.0002804 0.005157
254 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 12 1848 0.0002973 0.005447
255 REGULATION OF CELL ADHESION 7 629 0.0003047 0.005559
256 POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 3 64 0.0003282 0.005965
257 REGULATION OF HISTONE PHOSPHORYLATION 2 13 0.0003309 0.005968
258 NEGATIVE REGULATION OF CELL ACTIVATION 4 158 0.0003322 0.005968
259 RESPONSE TO PURINE CONTAINING COMPOUND 4 158 0.0003322 0.005968
260 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 5 289 0.0003342 0.00598
261 CELLULAR RESPONSE TO LIPID 6 457 0.0003597 0.006413
262 POSITIVE REGULATION OF NEURON DEATH 3 67 0.0003757 0.006647
263 REGULATION OF SISTER CHROMATID SEGREGATION 3 67 0.0003757 0.006647
264 REGULATION OF FIBRINOLYSIS 2 14 0.0003856 0.006744
265 RHYTHMIC PROCESS 5 298 0.0003846 0.006744
266 REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS 2 14 0.0003856 0.006744
267 REGULATION OF MAPK CASCADE 7 660 0.0004073 0.007098
268 NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION 3 69 0.0004097 0.007113
269 REGULATION OF MEMBRANE PERMEABILITY 3 70 0.0004274 0.007393
270 DENTATE GYRUS DEVELOPMENT 2 15 0.0004443 0.007628
271 RESPONSE TO VITAMIN E 2 15 0.0004443 0.007628
272 POSITIVE REGULATION OF KINASE ACTIVITY 6 482 0.0004772 0.008163
273 HIPPOCAMPUS DEVELOPMENT 3 73 0.0004835 0.008211
274 REGULATION OF ORGAN GROWTH 3 73 0.0004835 0.008211
275 HOMEOSTASIS OF NUMBER OF CELLS 4 175 0.0004891 0.008275
276 NEGATIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION 2 16 0.0005071 0.008504
277 NEGATIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION 2 16 0.0005071 0.008504
278 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 11 1672 0.0005081 0.008504
279 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 9 1152 0.000537 0.008955
280 NEGATIVE REGULATION OF CELL AGING 2 17 0.0005739 0.009537
281 MACROMOLECULE CATABOLIC PROCESS 8 926 0.0005946 0.009846
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY 7 28 1.219e-13 1.133e-10
2 CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 5 34 8.492e-09 3.945e-06
3 CYCLIN BINDING 4 19 6.363e-08 1.97e-05
4 KINASE REGULATOR ACTIVITY 7 186 1.101e-07 2.557e-05
5 PROTEIN COMPLEX BINDING 12 935 3.063e-07 5.691e-05
6 ENZYME BINDING 15 1737 1.171e-06 0.0001812
7 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 3 12 1.87e-06 0.0002481
8 KINASE BINDING 9 606 3.7e-06 0.0003437
9 ENZYME REGULATOR ACTIVITY 11 959 3.167e-06 0.0003437
10 MACROMOLECULAR COMPLEX BINDING 13 1399 3.406e-06 0.0003437
11 PROTEIN KINASE ACTIVITY 9 640 5.762e-06 0.0004866
12 KINASE ACTIVITY 10 842 7.157e-06 0.0005541
13 HISTONE KINASE ACTIVITY 3 19 8.151e-06 0.0005825
14 P53 BINDING 4 67 1.17e-05 0.0007762
15 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 10 992 2.969e-05 0.001839
16 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 3 30 3.361e-05 0.001936
17 PROTEIN SERINE THREONINE KINASE ACTIVITY 7 445 3.543e-05 0.001936
18 MOLECULAR FUNCTION REGULATOR 11 1353 7.922e-05 0.004088
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX 6 31 4.184e-11 2.443e-08
2 PROTEIN KINASE COMPLEX 6 90 3.23e-08 9.43e-06
3 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 6 237 9.541e-06 0.001857
4 CATALYTIC COMPLEX 10 1038 4.368e-05 0.005102
5 MICROTUBULE ORGANIZING CENTER 8 623 3.922e-05 0.005102
6 MICROTUBULE CYTOSKELETON 10 1068 5.558e-05 0.00523
7 CENTROSOME 7 487 6.268e-05 0.00523

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04115_p53_signaling_pathway 42 69 3.731e-111 6.715e-109
2 hsa04110_Cell_cycle 14 128 4.231e-21 3.808e-19
3 hsa04151_PI3K_AKT_signaling_pathway 11 351 1.096e-10 6.574e-09
4 hsa04210_Apoptosis 7 89 6.461e-10 2.907e-08
5 hsa04114_Oocyte_meiosis 6 114 1.333e-07 4.799e-06
6 hsa04914_Progesterone.mediated_oocyte_maturation 4 87 3.295e-05 0.0009886
7 hsa04510_Focal_adhesion 4 200 0.0008068 0.02075
8 hsa04650_Natural_killer_cell_mediated_cytotoxicity 3 136 0.002909 0.06187
9 hsa04120_Ubiquitin_mediated_proteolysis 3 139 0.003093 0.06187
10 hsa04390_Hippo_signaling_pathway 3 154 0.004125 0.07425
11 hsa00480_Glutathione_metabolism 2 50 0.004948 0.08096
12 hsa00240_Pyrimidine_metabolism 2 99 0.01836 0.2574
13 hsa04010_MAPK_signaling_pathway 3 268 0.01859 0.2574
14 hsa04530_Tight_junction 2 133 0.03178 0.4086
15 hsa04310_Wnt_signaling_pathway 2 151 0.04004 0.4805
16 hsa00230_Purine_metabolism 2 162 0.04545 0.5114

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

EMX2OS

 hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-130b-3p;hsa-miR-148a-5p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-224-3p;hsa-miR-26b-5p;hsa-miR-27a-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-33a-3p;hsa-miR-374b-3p;hsa-miR-421;hsa-miR-452-5p;hsa-miR-454-3p;hsa-miR-576-5p;hsa-miR-577;hsa-miR-590-3p;hsa-miR-592;hsa-miR-629-5p;hsa-miR-940 29 IGF1 Sponge network 1.057 0.31716 0.009 0.98747 0.587
2

CECR7

 hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-1275;hsa-miR-130b-3p;hsa-miR-148a-5p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-26b-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-33a-3p;hsa-miR-361-5p;hsa-miR-362-5p;hsa-miR-454-3p;hsa-miR-590-3p;hsa-miR-592;hsa-miR-629-5p 24 IGF1 Sponge network 0.551 0.56177 0.009 0.98747 0.513
3

EMX2OS

 hsa-let-7a-3p;hsa-let-7d-5p;hsa-let-7f-1-3p;hsa-miR-1304-5p;hsa-miR-151a-3p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-18b-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-29b-1-5p;hsa-miR-32-5p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-375;hsa-miR-421;hsa-miR-576-5p;hsa-miR-577;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-671-5p;hsa-miR-7-1-3p;hsa-miR-92a-3p;hsa-miR-940 31 THBS1 Sponge network 1.057 0.31716 0.376 0.83609 0.511
4

CECR7

 hsa-let-7a-3p;hsa-let-7d-5p;hsa-let-7f-1-3p;hsa-miR-1304-5p;hsa-miR-151a-3p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-18b-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-29b-1-5p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-375;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-671-5p;hsa-miR-7-1-3p 26 THBS1 Sponge network 0.551 0.56177 0.376 0.83609 0.491
5

CECR7

 hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-301a-3p;hsa-miR-30b-5p;hsa-miR-30c-5p;hsa-miR-30d-5p;hsa-miR-425-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-942-5p 10 SERPINE1 Sponge network 0.551 0.56177 0.967 0.43183 0.452
6

MEG3

 hsa-miR-1304-5p;hsa-miR-151a-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-29b-1-5p;hsa-miR-335-3p;hsa-miR-576-5p;hsa-miR-577;hsa-miR-590-5p;hsa-miR-671-5p;hsa-miR-7-1-3p 15 THBS1 Sponge network 0.433 0.33816 0.376 0.83609 0.414
7

ZNF883

 hsa-let-7a-3p;hsa-let-7d-5p;hsa-let-7f-1-3p;hsa-miR-1304-5p;hsa-miR-151a-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-29b-1-5p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-5p 18 THBS1 Sponge network 0.913 0.16772 0.376 0.83609 0.396
8

EMX2OS

 hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-301a-3p;hsa-miR-378a-5p;hsa-miR-421;hsa-miR-425-5p;hsa-miR-452-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-942-5p 10 SERPINE1 Sponge network 1.057 0.31716 0.967 0.43183 0.395
9

MEG3

 hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-186-5p;hsa-miR-20a-3p;hsa-miR-26b-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-374b-3p;hsa-miR-576-5p;hsa-miR-577 10 IGF1 Sponge network 0.433 0.33816 0.009 0.98747 0.37
10

CECR7

 hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-148a-3p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-18a-3p;hsa-miR-192-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-29b-1-5p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-362-5p;hsa-miR-425-5p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-671-5p;hsa-miR-93-5p;hsa-miR-942-5p 32 ZMAT3 Sponge network 0.551 0.56177 -0.325 0.50394 0.314
11

ZNF883

 hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-130b-3p;hsa-miR-148a-5p;hsa-miR-15b-3p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-26b-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-301a-3p;hsa-miR-33a-3p;hsa-miR-576-5p 15 IGF1 Sponge network 0.913 0.16772 0.009 0.98747 0.269
12

EMX2OS

 hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-144-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-192-3p;hsa-miR-19b-1-5p;hsa-miR-200b-5p;hsa-miR-20a-3p;hsa-miR-222-5p;hsa-miR-25-3p;hsa-miR-26b-3p;hsa-miR-29a-5p;hsa-miR-29b-1-5p;hsa-miR-301a-3p;hsa-miR-30d-3p;hsa-miR-32-3p;hsa-miR-32-5p;hsa-miR-33a-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-421;hsa-miR-576-5p;hsa-miR-577;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-625-5p;hsa-miR-7-1-3p;hsa-miR-877-5p 30 SESN3 Sponge network 1.057 0.31716 -0.016 0.97504 0.252
13 HCG11 hsa-miR-130b-3p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-222-5p;hsa-miR-26b-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-625-3p;hsa-miR-7-1-3p;hsa-miR-877-5p 11 SESN3 Sponge network 0.419 0.63279 -0.016 0.97504 0.251

Quest ID: 25922b7746d086a1c90c389b16b7a030